Artivion (NYSE:AORT) SVP Jean Holloway Sells 7,315 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 7,315 shares of Artivion stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $45.30, for a total transaction of $331,369.50. Following the completion of the transaction, the senior vice president owned 156,093 shares of the company’s stock, valued at $7,071,012.90. The trade was a 4.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Artivion Stock Performance

Shares of NYSE AORT traded down $0.11 during midday trading on Thursday, hitting $45.37. The company’s stock had a trading volume of 328,238 shares, compared to its average volume of 400,389. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -189.03 and a beta of 1.60. The company has a current ratio of 3.93, a quick ratio of 2.88 and a debt-to-equity ratio of 0.50. The stock has a fifty day moving average price of $43.96 and a 200 day moving average price of $38.00. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.04.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The business had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. The firm’s quarterly revenue was up 18.9% compared to the same quarter last year. On average, research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On Artivion

A number of large investors have recently added to or reduced their stakes in the company. Next Century Growth Investors LLC boosted its holdings in shares of Artivion by 107.6% in the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock worth $25,140,000 after purchasing an additional 530,122 shares in the last quarter. Champlain Investment Partners LLC purchased a new position in shares of Artivion during the 3rd quarter valued at about $17,912,000. Two Sigma Investments LP lifted its position in Artivion by 235.5% in the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after buying an additional 313,446 shares during the last quarter. Vanguard Group Inc. boosted its stake in Artivion by 8.3% in the third quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after buying an additional 232,424 shares in the last quarter. Finally, Voloridge Investment Management LLC grew its position in Artivion by 442.9% during the third quarter. Voloridge Investment Management LLC now owns 220,076 shares of the company’s stock valued at $9,318,000 after acquiring an additional 179,541 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on AORT shares. Needham & Company LLC lifted their price target on Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. LADENBURG THALM/SH SH cut Artivion from a “buy” rating to a “neutral” rating and upped their price target for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. Wall Street Zen raised shares of Artivion from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Finally, JMP Securities boosted their price objective on shares of Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a research note on Friday, October 10th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.